Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Standard
Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. / Derlin, Thorsten; Peldschus, Kersten; Münster, Silvia; Bannas, Peter; Herrmann, Jochen; Stübig, Thomas; Habermann, Christian R; Adam, Gerhard; Kröger, Nicolaus-Martin; Weber, Christoph.
in: EUR RADIOL, Jahrgang 23, Nr. 2, 01.02.2013, S. 570-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
AU - Derlin, Thorsten
AU - Peldschus, Kersten
AU - Münster, Silvia
AU - Bannas, Peter
AU - Herrmann, Jochen
AU - Stübig, Thomas
AU - Habermann, Christian R
AU - Adam, Gerhard
AU - Kröger, Nicolaus-Martin
AU - Weber, Christoph
PY - 2013/2/1
Y1 - 2013/2/1
N2 - OBJECTIVES: To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).METHODS: Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.RESULTS: One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.CONCLUSIONS: In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.
AB - OBJECTIVES: To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).METHODS: Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.RESULTS: One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.CONCLUSIONS: In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.
KW - Adult
KW - Aged
KW - Cohort Studies
KW - Confidence Intervals
KW - Disease-Free Survival
KW - Female
KW - Fluorodeoxyglucose F18
KW - Follow-Up Studies
KW - Graft Survival
KW - Humans
KW - Magnetic Resonance Imaging
KW - Male
KW - Middle Aged
KW - Multimodal Imaging
KW - Multiple Myeloma
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Postoperative Care
KW - Predictive Value of Tests
KW - Stem Cell Transplantation
KW - Survival Analysis
KW - Time Factors
KW - Tomography, X-Ray Computed
KW - Treatment Outcome
U2 - 10.1007/s00330-012-2600-5
DO - 10.1007/s00330-012-2600-5
M3 - SCORING: Journal article
C2 - 22843058
VL - 23
SP - 570
EP - 578
JO - EUR RADIOL
JF - EUR RADIOL
SN - 0938-7994
IS - 2
ER -